EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms

Anna Hinze, Jenny Rinke, Carl C Crodel, Susanne Möbius, Vivien Schäfer, Florian H Heidel, Andreas Hochhaus, Thomas Ernst iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Anna Hinze und 7 weiteren Autor:innen. Beteiligte Einrichtung: Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany. Hauptthemen laut MEDLINE: Neoplasms, Myeloproliferative Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2 , CALR and MPL genes provided new insights into their pathogenesis. Next‐generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony forming progenitor assays derived from single cells to study mutation acquisition. Further, the hierarchy of mutations within distinct cell lineages was evaluated. NGS revealed mutations in three epigenetic modulator genes ( TET2 , DNMT3A , ASXL1 ) as most common co‐mutations to the classical driver mutations. JAK2 V617F as well as DNMT3A and TET2 mutations were detected as primary events in disease formation and most cases presented with a linear mutation pattern. Mutations appear mostly in the myeloid lineages but can also appear in lymphoid subpopulations. In one case with a double mutant MPL gene, mutations exclusively appeared in the monocyte lineage. Overall, this study confirms the mutational heterogeneity of classical MPNs and highlights the role of JAK2 V617F and epigenetic modifier genes as early events in hematologic disease formation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMyeloproliferative DisordersHumansJanus Kinase 2Clonal EvolutionPhenotypeMutationCalreticulin

Stichwörter der Autor:innen

DNMT3AJAK2MPNTET2clonal evolutionclonal hierarchysingle cells

Substanzen

Janus Kinase 2Calreticulin

Autor:innen und Institutionen

  • Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
  • Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Jena, Germany.
  • Innere Medizin C, Universitätsmedizin Greifswald, Greifswald, Germany.

ORCID-Profile: Thomas Ernst

Zitieren

APA

Hinze, A., Rinke, J., Crodel, C. C., Möbius, S., Schäfer, V., Heidel, F. H., Hochhaus, A., & Ernst, T. (2023). Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms. British Journal of Haematology. https://doi.org/10.1111/bjh.18834

Vancouver

Hinze A, Rinke J, Crodel CC, Möbius S, Schäfer V, Heidel FH, et al. Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms. British Journal of Haematology. 2023. doi:10.1111/bjh.18834

BibTeX
@article{Hinze2023,
  author = {Hinze, Anna and Rinke, Jenny and Crodel, Carl C and Möbius, Susanne and Schäfer, Vivien and Heidel, Florian H and Hochhaus, Andreas and Ernst, Thomas},
  title = {Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18834}
}
Kostenlos starten →